The cannabis industry is not the primary thing that comes to your mind when you think of getting stocks. Further, those who are in the business and monitor its trend may say that the industry’s status is fluctuating and are getting worse. It is also note-taking that there are companies who struggle much with the financing aspect of the industry as learning the basic accounting is important.

According to professionals of Wall Street, investors must be reminded that even if the industry is facing great challenges, hidden treasures are waiting to be revealed which has the capability to deliver excellent returns.

Knowing this, there are game players within the industry that show compelling plays. They all have the right to be proud of their potential for the market’s share price. Let’s check them out.

Big Names on Cannabis Stocks

Here are marijuana companies soaring high in the weed industry.

Cresco Labs

OTC: CRLBF

Cresco Labs caters a diverse portfolio of brands complying a wide range of various needs. It has become interested in 11 states and about 21 dispensaries. These are in addition to their operations of cultivating and manufacturing.

To give respect to the federal state of Illinois, Cresco runs the business with license in various cultivation facilities and manufacturing plants compared to other cannabis businesses. Moreover, Cresco have the ability to expand its business. This is all in credits of a new financing firm that gives an initial amount of as high as $100 million and can increase the loan as an option.

Green Thumb Industries

OTC: GTBIF

This company became popular because of its goal of developing cannabis items for medical and legal use. The company self-declared that they are cannabis provider which are truly credible and experienced. In addition, Green Thumb also has a compelling potential in case cannabis is legalized on a wider coverage in which it will highly take place.

GW Pharmaceuticals

OTC: GWPH

GWPH is a company in the biopharma sector that has been part of the market and lead in cannabinoid therapeutics. Its popular product is the Epidiolex therapy that has already approved by the Food and Drug Administration as treatment for seizures associated diseases like Lennox-Gastaut syndrome or Dravet Syndrome. This was very remarkable for the cannabis industry as it was the first ever approved cannabis-based treatment from FDA. Moreover, the primary driver for GWPH will be the sales growth of Epidiolex. Yet, the probability of GWPH to rise on the cannabis stocks would fall at around 80% due to the average price target of $192.40.